

2019 Future of Rett Syndrome R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/25EBD42D1E0EN.html>

Date: February 2019

Pages: 80

Price: US\$ 2,199.00 (Single User License)

ID: 25EBD42D1E0EN

Abstracts

The global demand for Rett Syndrome treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Rett Syndrome pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Rett Syndrome pipeline companies from advancing their products into Phase 3 or Phase 4.

Rett Syndrome Report Description-

The 2019 pipeline study on Rett Syndrome pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Rett Syndrome pipeline compounds.

The Rett Syndrome pipeline guide presents information on all active drugs currently being developed for Rett Syndrome. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Rett Syndrome pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Rett Syndrome drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Rett Syndrome product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Rett Syndrome pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Rett Syndrome pipeline report includes-

An overview of Rett Syndrome disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Rett Syndrome pipeline

Company wise list of Rett Syndrome pipeline

Mechanism of Action wise Rett Syndrome pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Rett Syndrome pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Rett Syndrome pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Rett Syndrome pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL RETT SYNDROME PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Rett Syndrome Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Rett Syndrome pipeline, H1- 2019
- 3.5 Mechanism of Action wise Rett Syndrome Pipeline Candidates

4 AMO PHARMA LTD RETT SYNDROME PIPELINE DETAILS

- 4.1 AMO Pharma Ltd Business Profile
- 4.2 AMO Pharma Ltd Rett Syndrome Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 AMORSA THERAPEUTICS INC RETT SYNDROME PIPELINE DETAILS

- 5.1 Amorsa Therapeutics Inc Business Profile
- 5.2 Amorsa Therapeutics Inc Rett Syndrome Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 ANAVEX LIFE SCIENCES CORP RETT SYNDROME PIPELINE DETAILS

- 6.1 Anavex Life Sciences Corp Business Profile
- 6.2 Anavex Life Sciences Corp Rett Syndrome Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 ARMAGEN INC RETT SYNDROME PIPELINE DETAILS

- 7.1 ArmaGen Inc Business Profile
- 7.2 ArmaGen Inc Rett Syndrome Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 AVEXIS INC RETT SYNDROME PIPELINE DETAILS

- 8.1 AveXis Inc Business Profile
- 8.2 AveXis Inc Rett Syndrome Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD RETT SYNDROME PIPELINE DETAILS

- 9.1 Biohaven Pharmaceutical Holding Company Ltd Business Profile
- 9.2 Biohaven Pharmaceutical Holding Company Ltd Rett Syndrome Drug Details

9.3 Drug Snapshot

9.3.1 Originator

9.3.2 Collaborator/Co-Developer

9.3.3 Route of Administration

9.3.4 Orphan Drug/Fast Track/Special Designation

9.3.5 Geography

9.3.6 Type of Molecular Entity

9.3.7 Current Status

9.4 Drug Overview

9.5 Drug Mechanism of Action

9.6 Clinical/Pre-clinical Trial Details

9.7 Latest Drug Developments

10 COLD SPRING HARBOR LABORATORY RETT SYNDROME PIPELINE DETAILS

10.1 Cold Spring Harbor Laboratory Business Profile

10.2 Cold Spring Harbor Laboratory Rett Syndrome Drug Details

10.3 Drug Snapshot

10.3.1 Originator

10.3.2 Collaborator/Co-Developer

10.3.3 Route of Administration

10.3.4 Orphan Drug/Fast Track/Special Designation

10.3.5 Geography

10.3.6 Type of Molecular Entity

10.3.7 Current Status

10.4 Drug Overview

10.5 Drug Mechanism of Action

10.6 Clinical/Pre-clinical Trial Details

10.7 Latest Drug Developments

11 ELOXX PHARMACEUTICALS INC RETT SYNDROME PIPELINE DETAILS

11.1 Eloxx Pharmaceuticals Inc Business Profile

11.2 Eloxx Pharmaceuticals Inc Rett Syndrome Drug Details

11.3 Drug Snapshot

11.3.1 Originator

11.3.2 Collaborator/Co-Developer

11.3.3 Route of Administration

11.3.4 Orphan Drug/Fast Track/Special Designation

- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 GW PHARMACEUTICALS PLC RETT SYNDROME PIPELINE DETAILS

- 12.1 GW Pharmaceuticals Plc Business Profile
- 12.2 GW Pharmaceuticals Plc Rett Syndrome Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 MITOCHON PHARMACEUTICALS INC RETT SYNDROME PIPELINE DETAILS

- 13.1 Mitochon Pharmaceuticals Inc Business Profile
- 13.2 Mitochon Pharmaceuticals Inc Rett Syndrome Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action

- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14 MITSUBISHI TANABE PHARMA CORP RETT SYNDROME PIPELINE DETAILS

- 14.1 Mitsubishi Tanabe Pharma Corp Business Profile
- 14.2 Mitsubishi Tanabe Pharma Corp Rett Syndrome Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 NEUREN PHARMACEUTICALS LTD RETT SYNDROME PIPELINE DETAILS

- 15.1 Neuren Pharmaceuticals Ltd Business Profile
- 15.2 Neuren Pharmaceuticals Ltd Rett Syndrome Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16 NEUROLIXIS INC RETT SYNDROME PIPELINE DETAILS

- 16.1 Neurolix Inc Business Profile
- 16.2 Neurolix Inc Rett Syndrome Drug Details
- 16.3 Drug Snapshot
 - 16.3.1 Originator
 - 16.3.2 Collaborator/Co-Developer
 - 16.3.3 Route of Administration
 - 16.3.4 Orphan Drug/Fast Track/Special Designation
 - 16.3.5 Geography
 - 16.3.6 Type of Molecular Entity
 - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17 NEUROTROPE BIOSCIENCE INC RETT SYNDROME PIPELINE DETAILS

- 17.1 Neurotrope Bioscience Inc Business Profile
- 17.2 Neurotrope Bioscience Inc Rett Syndrome Drug Details
- 17.3 Drug Snapshot
 - 17.3.1 Originator
 - 17.3.2 Collaborator/Co-Developer
 - 17.3.3 Route of Administration
 - 17.3.4 Orphan Drug/Fast Track/Special Designation
 - 17.3.5 Geography
 - 17.3.6 Type of Molecular Entity
 - 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 NEWRON PHARMACEUTICALS SPA RETT SYNDROME PIPELINE DETAILS

- 18.1 Newron Pharmaceuticals SpA Business Profile
- 18.2 Newron Pharmaceuticals SpA Rett Syndrome Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer

- 18.3.3 Route of Administration
- 18.3.4 Orphan Drug/Fast Track/Special Designation
- 18.3.5 Geography
- 18.3.6 Type of Molecular Entity
- 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 OPKO HEALTH INC RETT SYNDROME PIPELINE DETAILS

- 19.1 OPKO Health Inc Business Profile
- 19.2 OPKO Health Inc Rett Syndrome Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 ORPHERIS INC RETT SYNDROME PIPELINE DETAILS

- 20.1 Orpheris Inc Business Profile
- 20.2 Orpheris Inc Rett Syndrome Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity
 - 20.3.7 Current Status

- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 PHARMATROPHIX INC RETT SYNDROME PIPELINE DETAILS

- 21.1 PharmatropHiX Inc Business Profile
- 21.2 PharmatropHiX Inc Rett Syndrome Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22 RELMADA THERAPEUTICS INC RETT SYNDROME PIPELINE DETAILS

- 22.1 Relmada Therapeutics Inc Business Profile
- 22.2 Relmada Therapeutics Inc Rett Syndrome Drug Details
- 22.3 Drug Snapshot
 - 22.3.1 Originator
 - 22.3.2 Collaborator/Co-Developer
 - 22.3.3 Route of Administration
 - 22.3.4 Orphan Drug/Fast Track/Special Designation
 - 22.3.5 Geography
 - 22.3.6 Type of Molecular Entity
 - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

23 STARWISE THERAPEUTICS LLC RETT SYNDROME PIPELINE DETAILS

- 23.1 Starwise Therapeutics LLC Business Profile
- 23.2 Starwise Therapeutics LLC Rett Syndrome Drug Details
- 23.3 Drug Snapshot
 - 23.3.1 Originator
 - 23.3.2 Collaborator/Co-Developer
 - 23.3.3 Route of Administration
 - 23.3.4 Orphan Drug/Fast Track/Special Designation
 - 23.3.5 Geography
 - 23.3.6 Type of Molecular Entity
 - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

24 ULTRAGENYX PHARMACEUTICAL INC RETT SYNDROME PIPELINE DETAILS

- 24.1 Ultragenyx Pharmaceutical Inc Business Profile
- 24.2 Ultragenyx Pharmaceutical Inc Rett Syndrome Drug Details
- 24.3 Drug Snapshot
 - 24.3.1 Originator
 - 24.3.2 Collaborator/Co-Developer
 - 24.3.3 Route of Administration
 - 24.3.4 Orphan Drug/Fast Track/Special Designation
 - 24.3.5 Geography
 - 24.3.6 Type of Molecular Entity
 - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

25. LATEST RETT SYNDROME DRUG PIPELINE DEVELOPMENTS, 2019

26. APPENDIX

- 26.1 About Us

26.2 Sources and Methodology

26.3 Contact Information

I would like to order

Product name: 2019 Future of Rett Syndrome R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/25EBD42D1E0EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/25EBD42D1E0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

